Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic

dc.date.accessioned	2023-03-06T07:32:29Z
dc.date.available	2023-03-06T07:32:29Z
dc.date.issued	2021
dc.identifier.citation	Turk J Med Sci. 2021 Aug 30;51(4):1615-1623. doi: 10.3906/sag-2012-5.
dc.identifier.uri	https://hdl.handle.net/20.500.12619/100334
dc.relation.isversionof	10.3906/sag-2012-5
dc.relation.isversionof	10.3906/sag-2012-5
dc.title	Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic
dc.relation.journal	Turk J Med Sci
dc.identifier.doi	10.3906/sag-2012-5
dc.contributor.author	Kalyoncu U
dc.contributor.author	Kalyoncu U
dc.contributor.author	Pehlivan Y
dc.contributor.author	Akar S
dc.contributor.author	Kaşifoğlu T
dc.contributor.author	Kimyon G
dc.contributor.author	Karadağ Ö
dc.contributor.author	Dalkılıç HE